Best Read Articles on Biosimilars in 2021
News about interchangeable Semglee (insulin glargine-yfgn) was among the most read in 2021.
Prime Therapeutics Adds the Biosimilar Semglee to Preferred Formulary
Prime’s formularies will include the insulin biosimilar over the reference product Lantus beginning in January 2022.
Read more
OptumRx Excludes the Diabetes Biosimilar Semglee from Formulary
OptumRx will favor the reference product Lantus on the Premium Formulary. The organization also released coverage information about other newly approved therapies.
Read more
Survey: Biosimilars are Gaining Momentum Among Payers
AmerisourceBergen/Xcenda survey finds payers believe biosimilars provide costs savings, and they are expected to continuing contracting with manufacturers.
Walgreens Offering Biosimilar and Interchangeable Insulin Semglee
Patients who are part of the Walgreen’s Prescription Savings Club can receive Semglee at up to 80% off the cash price.
Study: Medicare Part B Reimbursement Hinders Biosimilar Uptake
A reimbursement policy similar to that used for branded and generic drugs would have saved $1.6 billion from 2015 to 2019.
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More
